Combination preparations comprising SLV308 and a dopamine agonist
A composition containing SLV308 or its N-oxide, or at least one pharmacologically acceptable salt thereof: and L-DOPA or at least one pharmacologically acceptable salt thereof, for simultaneous, separate or sequential use in the treatment of disorders requiring recovery of dopaminergic function using this composition, including Parkinson's disease and restless leg syndrome.
1. A composition comprising (i) SLV308 N-oxide:
or at least one pharmacologically acceptable salt thereof, and (ii) L-DOPA, or at least one pharmacologically acceptable salt thereof, for simultaneous, separate or sequential use in therapy of at least one disorder requiring recovery of dopaminergic function.
2. A composition comprising (i) SLV308 or its N-oxide:
or at least one pharmacologically acceptable salt of these compounds,
(ii) L-DOPA, or at least one pharmacologically acceptable salt of thereof, and (iii) a decarboxylase inhibitor, for simultaneous, separate or sequential use in therapy of at least one disorder requiring recovery of dopaminergic function.
3. The composition as claimed in claim 2 , wherein the decarboxylase inhibitor is chosen from carbidopa and benserazide.
4. The composition as claimed in claim 1 , further comprising a COMT inhibitor.
5. The composition as claimed in claim 4 , wherein the COMT inhibitor is chosen from entacapone, nitecapone and tolcapone.
6. The composition as claimed in claim 2 , further comprising a COMT inhibitor.
7. The composition as claimed in claim 1 , further comprising an MAO-B inhibitor.
8. The composition as claimed in claim 7 , wherein the MAO-B inhibitor is chosen from deprenyl, (−)-deprenyl, desmethyldeprenyl, N-propargyl-1-(R)-aminoindan, phenelzine, tranyl-cypromine, CGP3466, furazolidone, isocarboxazid, pargyline, methyclothiazide and procarbazine.
9. The composition as claimed in claim 2 , further comprising an MAO-B inhibitor.
10. The composition as claimed in claim 3 , further comprising an MAO-B inhibitor.
11. A method for manufacturing a medicament for treating at least one disorder requiring recovery of dopaminergic function, said method comprising preparing a composition comprising (i) SLV308 N-oxide:
or at least one pharmacologically acceptable salt thereof, and (ii) L-DOPA or at least one pharmacologically acceptable salt thereof.
12. The method as claimed in claim 11 , wherein said at least one disorder is Parkinson's disease.
13. The method as claimed in claim 11 , wherein said at least one disorder is restless leg syndrome.
14. A pharmaceutical composition comprising at least one of a pharmaceutically acceptable carrier and at least one pharmaceutically acceptable auxiliary substance, and a pharmacologically active amount of a composition comprising (i) SLV308 N-oxide:
or at least one pharmacologically acceptable salt thereof, and (ii) L-DOPA or at least one pharmacologically acceptable salt thereof.
15. A kit comprising:
(i) a vessel containing SLV308 N-oxide, or at least one pharmacologically acceptable salt thereof,
(ii) a vessel containing L-DOPA or at least one pharmacologially acceptable salt thereof, and
(iii) instructions for the sequential, separate or simultaneous administration of SLV308 N-oxide and L-DOPA, to a patient in need thereof.
16. A method for preparing the kit of claim 15 comprising bringing a vessel containing SLV308 N-oxide, or at least one pharmacologically acceptable salt, thereof into association with a vessel containing L-DOPA or at least one pharmacologically acceptable salt thereof.
17. A method for manufacturing a medicament for treating at least one disorder requiring recovery of dopaminergic function, said method comprising preparing a composition comprising (i) SLV308 or its N-oxide:
or at least one pharmacologically acceptable salt of these compounds, (ii) L-DOPA or at least one pharmacologically acceptable salt thereof, and (iii) a decarboxylase inhibitor.
18. A pharmaceutical composition comprising at least one of a pharmaceutically acceptable carrier and at least one pharmaceutically acceptable auxiliary substance, and a pharmacologically active amount of a composition comprising (i) SLV308 or its N-oxide:
or at least one pharmacologically acceptable salt of these compounds, (ii) L-DOPA or at least one pharmacologically acceptable salt thereof, and (iii) a decarboxylase inhibitor.
19. The composition as claimed in claim 1 , further comprising a decarboxylase inhibitor.